# MLTX catalysts: MoonLake Immunotherapeutics PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/mltx/catalysts

> MoonLake Immunotherapeutics (MLTX) has 10 upcoming catalysts. The next is the HiSCR100 topline data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for MLTX?

MoonLake Immunotherapeutics (MLTX) has 10 upcoming catalysts. The next is the HiSCR100 topline data readout, Q1 2027. SEC Form 10-Q: "We expect to complete the VELA-TEEN clinical trial in the fourth quarter of 2026 and to announce final topline results in the first quarter of 2027." [Calendar and source filings](https://sec-api.dev/companies/mltx/catalysts)

Source: SEC Form 10-Q, accession 0001821586-26-000015, https://www.sec.gov/Archives/edgar/data/1821586/000182158626000015/mnlk-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/companies/mltx/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | MoonLake Immunotherapeutics |
| Ticker | MLTX (Nasdaq) |
| SEC CIK | 1821586 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/mltx |

## Cash runway

Cash $498.5M as of 2026-09-30; quarterly burn $63.4M; about 23.6 months of runway at that rate (XBRL company facts, accession 0001821586-26-000015).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 2022 | [MoonLake Immunotherapeutics topline data readout](https://sec-api.dev/companies/mltx/catalysts) | MLTX | moderate-to-severe HS | completed, met | "In May 2022, we initiated a Phase 2b trial of SLK in patients with moderate-to-severe HS (the MIRA trial (M1095-HS-201)), and in June 2023, we announced positive top-line results from this trial, which met its primary endpoint of Hidradenitis Suppurativa Clinical Response ("HiSCR") 75." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1821586/000182158625000022/mnlk-20250930.htm)) |
| Dec 2022 | [PSA-201 trial start](https://sec-api.dev/pdufa/psa-201) | MLTX | active PsA | completed | "In December 2022, we initiated a Phase 2b trial in patients with active PsA (the ARGO trial (M1095-PSA-201)) and in November 2023, we announced positive top-line results from this trial, which met its primary endpoint of American College of Rheumatology ("ACR") 50." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1821586/000182158625000022/mnlk-20250930.htm)) |
| Dec 2022 | [PSA-201 topline data readout](https://sec-api.dev/pdufa/psa-201) | MLTX | active PsA | completed, met | "In December 2022, we initiated a Phase 2b trial in patients with active PsA (the ARGO trial (M1095-PSA-201)) and in November 2023, we announced positive top-line results from this trial, which met its primary endpoint of American College of Rheumatology ("ACR") 50." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1821586/000182158625000022/mnlk-20250930.htm)) |
| Jun 2023 | [MoonLake Immunotherapeutics topline data readout](https://sec-api.dev/companies/mltx/catalysts) | MLTX |  | completed, positive | "In May 2022, we initiated our MIRA trial, and in June 2023, we announced positive top-line results from this trial." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000002/mnlk-20251231.htm)) |
| Jun 2023 | [MoonLake Immunotherapeutics topline data readout](https://sec-api.dev/companies/mltx/catalysts) | MLTX | moderate-to-severe HS | completed, met | "In May 2022, we initiated a Phase 2b trial of SLK in patients with moderate-to-severe HS (the MIRA trial (M1095-HS-201)), and in June 2023, we announced positive top-line results from this trial, which met its primary endpoint of Hidradenitis Suppurativa Clinical Response ("HiSCR") 75 with 43% of patients treated with SLK 120mg achieving such response at week 12." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000007/mnlk-20260331.htm)) |
| Oct 2023 | [MoonLake Immunotherapeutics topline data readout](https://sec-api.dev/companies/mltx/catalysts) | MLTX | moderate-to-severe HS | completed, positive | "In October 2023, we announced positive 24-week top-line results showing that the maintenance treatment with SLK led to further improvements in HiSCR75 response rates and other clinically relevant outcomes in patients with moderate-to-severe HS." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000007/mnlk-20260331.htm)) |
| Nov 2023 | [PSA-201 trial start](https://sec-api.dev/pdufa/psa-201) | MLTX | active PsA | completed | "In December 2022, we initiated a Phase 2b trial in patients with active PsA (the ARGO trial (M1095-PSA-201)) and in November 2023, we announced positive top-line results from this trial, which met its primary endpoint of American College of Rheumatology ("ACR") 50 with 46% of patients on 60mg SLK achieving such response at week 12." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000007/mnlk-20260331.htm)) |
| Nov 2023 | [PSA-201 topline data readout](https://sec-api.dev/pdufa/psa-201) | MLTX | active PsA | completed, met | "In December 2022, we initiated a Phase 2b trial in patients with active PsA (the ARGO trial (M1095-PSA-201)) and in November 2023, we announced positive top-line results from this trial, which met its primary endpoint of American College of Rheumatology ("ACR") 50 with 46% of patients on 60mg SLK achieving such response at week 12." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000007/mnlk-20260331.htm)) |
| Nov 2024 | [PPP-201 trial start](https://sec-api.dev/pdufa/ppp-201) | MLTX |  | completed | "In November 2024, we initiated a Phase 2 trial in patients with PPP (the LEDA trial (M1095-PPP-201)) and in November 2025, we presented positive results of this trial, suggesting that SLK could provide clinically meaningful improvements in patients with PPP." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000007/mnlk-20260331.htm)) |
| February 26, 2025 | [MoonLake Immunotherapeutics earnings report](https://sec-api.dev/companies/mltx/catalysts) | MLTX |  | completed | "MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000182158625000004/moonlake-pressreleasexq420.htm)) |
| May 12, 2025 | [MoonLake Immunotherapeutics earnings report](https://sec-api.dev/companies/mltx/catalysts) | MLTX |  | completed | "MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000182158625000009/moonlake-pressreleasexq120.htm)) |
| August 5, 2025 | [MoonLake Immunotherapeutics earnings report](https://sec-api.dev/companies/mltx/catalysts) | MLTX |  | completed | "MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000182158625000016/moonlake-pressreleasexq220.htm)) |
| August 14, 2025 | [Sonelokimab primary completion](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Hidradenitis Suppurativa | completed | "NCT06411379 (Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-14 (ACTUAL); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06411379)) |
| Sep 2025 | [Sonelokimab topline data readout](https://sec-api.dev/pdufa/sonelokimab) | MLTX |  | scheduled | "•Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the United States in mid-2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000182158625000016/moonlake-pressreleasexq220.htm)) |
| September 2, 2025 | [Sonelokimab primary completion](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Hidradenitis Suppurativa | completed | "NCT06411899 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-02 (ACTUAL); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06411899)) |
| Q4 2025 | [MoonLake Immunotherapeutics PDUFA date](https://sec-api.dev/companies/mltx/catalysts) | MLTX |  | scheduled | "PDUFA, Prescription Drug User Fee Act Q2: Pre-BLA CMC meeting completed Q4 25: Type B FDA meeting completed" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000121390026070362/ea029539901ex99-2.htm)) |
| November 5, 2025 | [Sonelokimab earnings report](https://sec-api.dev/pdufa/sonelokimab) | MLTX |  | completed | "MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000182158625000021/moonlake-pressreleasexq320.htm)) |
| February 18, 2026 | [Sonelokimab earnings report](https://sec-api.dev/pdufa/sonelokimab) | MLTX |  | completed | "Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000121390026018967/ea027791001ex99-1_moonlake.htm)) |
| Q2 2026 | [MoonLake Immunotherapeutics topline data readout](https://sec-api.dev/companies/mltx/catalysts) | MLTX |  | scheduled | "The trial is expected to enroll a total of 30-35 patients and we expect topline results in the second quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1821586/000182158625000022/mnlk-20250930.htm)) |
| May 10, 2026 | [MoonLake Immunotherapeutics earnings report](https://sec-api.dev/companies/mltx/catalysts) | MLTX |  | completed | "MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000005/moonlake-pressreleasexq120.htm)) |
| May 28, 2026 | [Sonelokimab primary completion](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Arthritis, Psoriatic | completed | "NCT06641076 (Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-28 (ACTUAL); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06641076)) |
| Q3 2026 | [Sonelokimab trial start](https://sec-api.dev/pdufa/sonelokimab) | MLTX |  | scheduled | "The Company expects to commence a Phase 3 clinical trial in PPP in Q3 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000182158625000021/moonlake-pressreleasexq320.htm)) |
| 2H 2026 | [MoonLake Immunotherapeutics topline data readout](https://sec-api.dev/companies/mltx/catalysts) | MLTX |  | scheduled | "We expect to announce topline results from the VELA-TEEN clinical trial in the second half of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000007/mnlk-20260331.htm)) |
| 2H 2026 | [HiSCR100 topline data readout](https://sec-api.dev/pdufa/hiscr100) | MLTX |  | scheduled | "We expect to announce final topline results from the VELA-TEEN clinical trial in the second half of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000010/mnlk-20260630.htm)) |
| August 10, 2026 | [Sonelokimab topline data readout](https://sec-api.dev/pdufa/sonelokimab) | MLTX |  | completed, positive | "MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced positive topline results from the Phase 3 IZAR-1 trial evaluating sonelokimab in biologic-na&iuml;ve adults with active psoriatic arthritis (PsA) and reported second quarter 2026 financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000121390026086939/ea030119101ex99-1.htm)) |
| August 10, 2026 | [Sonelokimab earnings report](https://sec-api.dev/pdufa/sonelokimab) | MLTX |  | completed | "MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000121390026086939/ea030119101ex99-1.htm)) |
| Sep 2026 | [Sonelokimab NDA/BLA acceptance](https://sec-api.dev/pdufa/sonelokimab) | MLTX |  | scheduled | "•With no remaining gaps identified, the pre-BLA process for HS is complete, and the BLA submission to the FDA is planned for the end of September 2026; acceptance, including a decision on Priority Review designation associated with the inclusion of VELA-TEEN adolescent data, is expected by end of November 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000005/moonlake-pressreleasexq120.htm)) |
| September 28, 2026 | [Sonelokimab primary completion](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Hidradenitis Suppurativa | completed | "NCT06768671 (An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-28 (ACTUAL); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06768671)) |
| Sep to Dec 2026 | [Sonelokimab topline data readout](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Hidradenitis Suppurativa | scheduled | "NCT06768671 (An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-28 (ACTUAL); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06768671)) |
| September 30, 2026 | [Sonelokimab NDA/BLA submission](https://sec-api.dev/pdufa/sonelokimab) | MLTX | moderate-to-severe hidradenitis suppurativa | completed | "On September 30, 2026, the Company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), seeking approval of sonelokimab (SLK) for the treatment of moderate-to-severe hidradenitis suppurativa (HS) in adults and pediatric patients 12 years of age and older." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000013/moonlake-pressreleasexq320.htm)) |
| September 30, 2026 | [MoonLake Immunotherapeutics NDA/BLA acceptance](https://sec-api.dev/companies/mltx/catalysts) | MLTX |  | completed | "As of September 30, 2026, the Company made a total of €7.5 million ($8.1 million using the then applicable exchange rate) in additional milestone payments and accrued €15.0 million ($17.0 million using the period end exchange rate) for a regulatory milestone associated with FDA acceptance of the Company's BLA submission for SLK." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000015/mnlk-20260930.htm)) |
| Nov 2026 | [PPP-301 trial start](https://sec-api.dev/pdufa/ppp-301) | MLTX |  | scheduled | "We expect to commence enrollment for the Phase 3 NOVA trial (M1095-PPP-301) in November 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000015/mnlk-20260930.htm)) |
| Nov 2026 | [Sonelokimab trial start](https://sec-api.dev/pdufa/sonelokimab) | MLTX |  | scheduled | "The Company expects to commence enrollment in the Phase 3 NOVA trial as per plans in November 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000013/moonlake-pressreleasexq320.htm)) |
| Nov 2026 | [Sonelokimab PDUFA date](https://sec-api.dev/pdufa/sonelokimab) | MLTX |  | scheduled | "Clarity on the Prescription Drug User Fee Act (PDUFA) date is currently expected by the end of November 2026, concurrent with the FDA's acceptance of the BLA." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000121390026070362/ea029539901ex99-1.htm)) |
| November 4, 2026 | [MoonLake Immunotherapeutics earnings report](https://sec-api.dev/companies/mltx/catalysts) | MLTX |  | completed | "MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000013/moonlake-pressreleasexq320.htm)) |
| Q1 2027 | [HiSCR100 topline data readout](https://sec-api.dev/pdufa/hiscr100) | MLTX |  | scheduled | "We expect to complete the VELA-TEEN clinical trial in the fourth quarter of 2026 and to announce final topline results in the first quarter of 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000015/mnlk-20260930.htm)) |
| Q1 2027 | [Sonelokimab interim data readout](https://sec-api.dev/pdufa/sonelokimab) | MLTX |  | scheduled | "•Enrollment completed in the Phase 3 IZAR-2 trial in psoriatic arthritis, with initial topline results expected in Q1 2027 following the predefined unblinding protocol" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000013/moonlake-pressreleasexq320.htm)) |
| Q1 2027 | [Sonelokimab topline data readout](https://sec-api.dev/pdufa/sonelokimab) | MLTX |  | scheduled | "◦Expected to conclude VELA-TEEN clinical trial in Q4 2026 and present final topline results at a scientific meeting in the first quarter of 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000013/moonlake-pressreleasexq320.htm)) |
| Q1 2027 | [PSA-302 interim data readout](https://sec-api.dev/pdufa/psa-302) | MLTX |  | scheduled | "We expect to announce initial topline results following a predefined unblinding protocol in the first quarter of 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000015/mnlk-20260930.htm)) |
| January 2027 | [Sonelokimab primary completion](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Arthritis, Psoriatic | scheduled | "NCT06641089 (Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-04 (ESTIMATED); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06641089)) |
| Q2 2027 | [Sonelokimab topline data readout](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Arthritis, Psoriatic | scheduled | "◦IZAR-1: Expected to announce Week 52 topline results in Q2 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000013/moonlake-pressreleasexq320.htm)) |
| Feb to May 2028 | [Sonelokimab topline data readout](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Arthritis, Psoriatic | scheduled | "NCT07223138 (A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-02-04 (ESTIMATED); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07223138)) |
| February 2028 | [Sonelokimab primary completion](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Arthritis, Psoriatic | scheduled | "NCT07223138 (A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-02-04 (ESTIMATED); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07223138)) |
| Jun to Sep 2028 | [Sonelokimab topline data readout](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Hidradenitis Suppurativa | scheduled | "NCT07007637 (A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-06-13 (ESTIMATED); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07007637)) |
| June 2028 | [Sonelokimab primary completion](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Hidradenitis Suppurativa | scheduled | "NCT07007637 (A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-06-13 (ESTIMATED); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07007637)) |

## Drugs

- [HiSCR100](https://sec-api.dev/pdufa/hiscr100): 
- [PPP-201](https://sec-api.dev/pdufa/ppp-201): 
- [PPP-301](https://sec-api.dev/pdufa/ppp-301): 
- [PSA-201](https://sec-api.dev/pdufa/psa-201): active psa
- [PSA-302](https://sec-api.dev/pdufa/psa-302): 
- [Sonelokimab](https://sec-api.dev/pdufa/sonelokimab): moderate-to-severe hidradenitis suppurativa, Hidradenitis Suppurativa, Arthritis, Psoriatic

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/mltx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MLTX catalysts: MoonLake Immunotherapeutics PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/mltx/catalysts

```bibtex
@misc{secapidev_companies_mltx_catalysts_20261116,
  title        = {MLTX catalysts: MoonLake Immunotherapeutics PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/mltx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_mltx_catalysts_20261116","title":"MLTX catalysts: MoonLake Immunotherapeutics PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/mltx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
